17th May 2016
IDAC Enters an agreement with ONO PHARMACEUTICAL relating to
Exclusive Evaluation and License Negotiation on IT1208, anti-CD4 antibody
IDAC Theranostics, Inc. (Tokyo, Japan; President, Satoru Ito; “IDAC”) announced that it entered into
an option agreement with ONO PHARMACEUTICAL CO., LTD. (Osaka, Japan; President, Representative
Director, Gyo Sagara; ”ONO”) on May 16, 2016, under with ONO is granted a right for exclusive evaluation
and license negotiation on IT1208, a humanized anti-CD4 antibody being developed by IDAC.
During the term of such agreement, IDAC will conduct PhaseⅠstudy of IT1208 in solid tumors in Japan.
IT1208 transiently depletes CD4+ T cells and removes an immunosuppressive environment, leading to
activation of antitumor immunity mediated mainly by CD8+ T cells. In preclinical studies, anti-CD4 antibody
has demonstrated a potent antitumor activity in tumor-bearing mice.
About anti CD4 antibody(IT1208)
IT1208 is a humanized anti-CD4 antibody with an enhanced antibody-dependent-cellular cytotoxicity(ADCC)
activity using Potelligent technology from Kyowa Hakko Kirin Co., Ltd.
About IDAC Theranostics, Inc.
IDAC Theranostics, Inc. was established on April 2, 2012 , by Koji Matsushima, Professor of Graduate School of
Medicine, The University of Tokyo and others, and it has been developing IT1208, which was licensed from Kyowa
Hakko Kirin Co., Ltd. as a drug candidate.
For more information, please visit the company’s website at http://www.idac-thera.com
About ONO PHARMACEUTICAL CO.,LTD
ONO PHAMACEUTICAL CO., LTD, headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company
committed to creating innovative medicines in specific areas. It focuses especially on the oncology and diabetes areas.
For more information, please visit the company’s website at http://www.ono.co.jp/eng/index.html.
Contact
IDAC Theranostics, Inc.
Administrative and Operations
info-idac@idac-thera.com